First-line zanidatamab–chemotherapy with or without tislelizumab improves survival in advanced-stage HER2+ GEA
D
Diana Romero
Article Details
Journal
Nature Reviews Clinical Oncology
Volume / Issue
Vol. 23, Issue 7
Published
July 01, 2026
Pages
476-476
ISSN
1759-4774
Publisher
Springer Science and Business Media LLC
Journal Info
Nature Reviews Clinical Oncology
Springer Science and Business Media LLC
ISSN: 1759-4774 Q1 Medicine
Authors (1)
D
Diana Romero
Related Articles from this Journal
Ibrutinib improves overall survival in patients with mantle cell lymphoma
Peter Sidaway
Jul 2026
10.1038/s41571-026-01166-7
Clinical implementation of multi-cancer early detection tests: can we find a path forward?
Ariadna Tibau, Aaron S. Kesselheim
Jul 2026
10.1038/s41571-026-01158-7
Pan-RAS inhibitor daraxonrasib shows promise in pancreatic cancer
David Killock
Jul 2026
10.1038/s41571-026-01162-x
Liquid biopsy to inform adjuvant decisions during neoadjuvant chemotherapy — a full-circle moment for nasopharyngeal cancer
W. K. Jacky Lam, Brigette B. Y. Ma
Jul 2026
10.1038/s41571-026-01157-8
Synergistic integration of regional and systemic therapies in uveal melanoma
Shaheer A. Khan, Richard D. Carvajal
Jul 2026
10.1038/s41571-026-01155-w